Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 6/20 | 0.38 |
| ▸ | RAB9A | P51151 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 5/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 5/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 4/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27064650 | 1.00 | MEN1 (0.41) | MEN1KMT2AALOX5NPC1RAB9A | |
| SCHEMBL9440202 | 1.00 | MEN1 (0.41) | MEN1KMT2AALOX5NPC1RAB9A | |
| SCHEMBL4143578 | 0.98 | MEN1 (0.42) | MEN1KMT2AALOX5NPC1RAB9A | |
| SCHEMBL9440179 | 0.92 | MEN1 (0.47) | MEN1KMT2AALOX5NPC1RAB9A | |
| SCHEMBL474116 | 0.92 | ALOX5 (0.46) | MEN1KMT2AALOX5NPC1RAB9A | |
| SCHEMBL9440188 | 0.92 | ALOX5 (0.46) | MEN1KMT2AALOX5NPC1RAB9A | |
| SCHEMBL10512029 | 0.92 | HRH3 (0.47) | MEN1KMT2AKDM4ELTA4HHRH3 | |
| SCHEMBL9440237 | 0.90 | MEN1 (0.48) | MEN1KMT2AALOX5NPC1RAB9A | |
| SCHEMBL9440178 | 0.84 | MEN1 (0.50) | MEN1KMT2AALOX5NPC1RAB9A | |
| SCHEMBL1956432 | 0.82 | KMT2A (0.42) | MEN1KMT2ARAB9ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215888-A1 | TOPICAL NAIL FORMULATION | NUVO RESEARCH INC. (CA) | 2009-08-27 | — | — | US | claimed |
| EP-1909772-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | Nuvo Research Inc. (CA) | 2008-04-16 | — | — | EP | claimed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | claimed |
| WO-2007098591-A2 | TOPICAL NAIL FORMULATION | NUVO RESEARCH INC. (CA) | 2007-09-07 | — | — | WO | claimed |
| WO-2007016766-A1 | TRANSDERMAL DRUG DELIVERY FORMULATION | NUVO RESEARCH INC. (CA) | 2007-02-15 | — | — | WO | claimed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | claimed |
| US-5270346-A | Penetration enhancers for transdermal delivery of systemic agents | WHITBY RESEARCH, INC. (US) | 1993-12-14 | — | — | US | claimed |
| US-5218113-A | To enhance the penetration of physiologically active agent through the skin or other membrane | WHITBY RESEARCH, INC. (US) | 1993-06-08 | — | — | US | claimed |
| EP-0257063-B1 | COMPOSITIONS COMPRISING 1-SUBSTITUTED AZACYCLOALKANES AND THEIR USES | WHITBY RESEARCH, Inc. (US) | 1992-06-17 | — | — | EP | claimed |
| EP-0257063-A4 | COMPOSITIONS COMPRISING 1-SUBSTITUTED AZACYCLOALKANES AND THEIR USES. | NELSON RES & DEV COMPANY (US) | 1989-04-24 | — | — | EP | claimed |
| EP-0257063-A1 | COMPOSITIONS COMPRISING 1-SUBSTITUTED AZACYCLOALKANES AND THEIR USES. | NELSON RES & DEV (US) | 1988-03-02 | — | — | EP | claimed |
| WO-1987004706-A1 | COMPOSITIONS COMPRISING 1-SUBSTITUTED AZACYCLOALKANES AND THEIR USES | NELSON RESEARCH AND DEVELOPMENT COMPANY (US) | 1987-08-13 | — | — | WO | claimed |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| WO-2024018866-A1 | COLLECTOR AND ORE FLOATATION METHOD | 住友化学株式会社 | 2024-01-25 | — | — | WO | disclosed |
| US-20230263731-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. | 2023-08-24 | — | — | US | disclosed |
| EP-0257063-A4 | COMPOSITIONS COMPRISING 1-SUBSTITUTED AZACYCLOALKANES AND THEIR USES. | NELSON RES & DEV COMPANY (US) | 1989-04-24 | — | — | EP | disclosed |
| WO-1988002626-A1 | PENETRATION ENHANCERS FOR TRANSDERMAL DELIVERY OF SYSTEMIC AGENTS | NELSON RESEARCH AND DEVELOPMENT COMPANY (US) | 1988-04-21 | — | — | WO | disclosed |
| EP-0257063-A1 | COMPOSITIONS COMPRISING 1-SUBSTITUTED AZACYCLOALKANES AND THEIR USES. | NELSON RES & DEV (US) | 1988-03-02 | — | — | EP | disclosed |
| WO-1987004706-A1 | COMPOSITIONS COMPRISING 1-SUBSTITUTED AZACYCLOALKANES AND THEIR USES | NELSON RESEARCH AND DEVELOPMENT COMPANY (US) | 1987-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | ARID2, ACIN1, TP53 | MEN1 1571/4885KMT2A 3780/4885ALOX5 2995/4885 |
| US-20230263731-A1 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | ARID2, ACIN1, TP53 | MEN1 1571/4885KMT2A 3780/4885ALOX5 2995/4885 |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | MEN1 4840/4885KMT2A 2718/4885ALOX5 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.